Cargando…
Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients
BACKGROUND: Ovarian cancer is a lethal gynecological cancer and no reliable minimally invasive early diagnosis tools exist. High grade serous ovarian carcinoma (HGSOC) is often diagnosed at advanced stages, resulting in poorer outcome than those diagnosed in early stage. Circulating microRNAs have b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676310/ https://www.ncbi.nlm.nih.gov/pubmed/37934368 http://dx.doi.org/10.1007/s11033-023-08795-6 |
_version_ | 1785141253166333952 |
---|---|
author | Petersen, Patrick H.D. Lopacinska-Jørgensen, Joanna Høgdall, Claus K. Høgdall, Estrid V. |
author_facet | Petersen, Patrick H.D. Lopacinska-Jørgensen, Joanna Høgdall, Claus K. Høgdall, Estrid V. |
author_sort | Petersen, Patrick H.D. |
collection | PubMed |
description | BACKGROUND: Ovarian cancer is a lethal gynecological cancer and no reliable minimally invasive early diagnosis tools exist. High grade serous ovarian carcinoma (HGSOC) is often diagnosed at advanced stages, resulting in poorer outcome than those diagnosed in early stage. Circulating microRNAs have been investigated for their biomarker potential. However, due to lack of standardization methods for microRNA detection, there is no consensus, which microRNAs should be used as stable endogenous controls. We aimed to identify microRNAs that are stably expressed in plasma of HGSOC and benign ovarian tumor patients. METHODS AND RESULTS: We isolated RNA from plasma samples of 60 HGSOC and 48 benign patients. RT-qPCR was accomplished with a custom panel covering 40 microRNAs and 8 controls. Stability analysis was performed using five algorithms: Normfinder, geNorm, Delta-Ct, BestKeeper and RefFinder using an R-package; RefSeeker developed by our study group [1]. Among 41 analyzed RNAs, 13 were present in all samples and eligible for stability analysis. Differences between stability rankings were observed across algorithms. In HGSOC samples, hsa-miR-126-3p and hsa-miR-23a-3p were identified as the two most stable miRNAs. In benign samples, hsa-miR-191-5p and hsa-miR-27a-3p were most stable. In the combined HGSOC and benign group, hsa-miR-23a-3p and hsa-miR-27a-3p were identified by both the RefFinder and Normfinder analysis as the most stable miRNAs. CONCLUSIONS: Consensus regarding normalization approaches in microRNA studies is needed. The choice of endogenous microRNAs used for normalization depends on the histological content of the cohort. Furthermore, normalization also depends on the algorithms used for stability analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-023-08795-6. |
format | Online Article Text |
id | pubmed-10676310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-106763102023-11-07 Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients Petersen, Patrick H.D. Lopacinska-Jørgensen, Joanna Høgdall, Claus K. Høgdall, Estrid V. Mol Biol Rep Original Article BACKGROUND: Ovarian cancer is a lethal gynecological cancer and no reliable minimally invasive early diagnosis tools exist. High grade serous ovarian carcinoma (HGSOC) is often diagnosed at advanced stages, resulting in poorer outcome than those diagnosed in early stage. Circulating microRNAs have been investigated for their biomarker potential. However, due to lack of standardization methods for microRNA detection, there is no consensus, which microRNAs should be used as stable endogenous controls. We aimed to identify microRNAs that are stably expressed in plasma of HGSOC and benign ovarian tumor patients. METHODS AND RESULTS: We isolated RNA from plasma samples of 60 HGSOC and 48 benign patients. RT-qPCR was accomplished with a custom panel covering 40 microRNAs and 8 controls. Stability analysis was performed using five algorithms: Normfinder, geNorm, Delta-Ct, BestKeeper and RefFinder using an R-package; RefSeeker developed by our study group [1]. Among 41 analyzed RNAs, 13 were present in all samples and eligible for stability analysis. Differences between stability rankings were observed across algorithms. In HGSOC samples, hsa-miR-126-3p and hsa-miR-23a-3p were identified as the two most stable miRNAs. In benign samples, hsa-miR-191-5p and hsa-miR-27a-3p were most stable. In the combined HGSOC and benign group, hsa-miR-23a-3p and hsa-miR-27a-3p were identified by both the RefFinder and Normfinder analysis as the most stable miRNAs. CONCLUSIONS: Consensus regarding normalization approaches in microRNA studies is needed. The choice of endogenous microRNAs used for normalization depends on the histological content of the cohort. Furthermore, normalization also depends on the algorithms used for stability analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11033-023-08795-6. Springer Netherlands 2023-11-07 2023 /pmc/articles/PMC10676310/ /pubmed/37934368 http://dx.doi.org/10.1007/s11033-023-08795-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Petersen, Patrick H.D. Lopacinska-Jørgensen, Joanna Høgdall, Claus K. Høgdall, Estrid V. Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title | Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title_full | Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title_fullStr | Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title_full_unstemmed | Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title_short | Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
title_sort | identification of stably expressed micrornas in plasma from high-grade serous ovarian carcinoma and benign tumor patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676310/ https://www.ncbi.nlm.nih.gov/pubmed/37934368 http://dx.doi.org/10.1007/s11033-023-08795-6 |
work_keys_str_mv | AT petersenpatrickhd identificationofstablyexpressedmicrornasinplasmafromhighgradeserousovariancarcinomaandbenigntumorpatients AT lopacinskajørgensenjoanna identificationofstablyexpressedmicrornasinplasmafromhighgradeserousovariancarcinomaandbenigntumorpatients AT høgdallclausk identificationofstablyexpressedmicrornasinplasmafromhighgradeserousovariancarcinomaandbenigntumorpatients AT høgdallestridv identificationofstablyexpressedmicrornasinplasmafromhighgradeserousovariancarcinomaandbenigntumorpatients |